Dr. Henrik Lindberg

Former Medical Director, Novo Nordisk — Copenhagen, Denmark

Dr. Henrik Lindberg is an endocrinologist and obesity medicine specialist with over 18 years of clinical and industry experience.

He spent 4 years at Novo Nordisk as Medical Director for the metabolic diseases portfolio, including overseeing the launch of Wegovy® (semaglutide) across European markets. This experience gave him deep expertise in GLP-1 receptor agonists and the rapidly evolving obesity therapeutics landscape.

His career spans academic medicine (Karolinska, Rigshospitalet), pharmaceutical industry (Novo Nordisk), and digital health (CMO at a metabolic health startup).

• GLP-1 receptor agonists (Semaglutide, Tirzepatide, Liraglutide)
• Obesity medicine and weight management
• Type 2 diabetes and metabolic syndrome
• Clinical trials (Phase II-IV)
• Real-world evidence studies

• Fellowship in Obesity Medicine — Harvard Medical School / Joslin Diabetes Center (2014-2015)
• PhD in Metabolic Disorders — University of Copenhagen (2010-2014)
• Doctor of Medicine (MD) — Karolinska Institutet, Stockholm (2000-2006)

• Lindberg H, et al. "Long-term cardiovascular outcomes with GLP-1 receptor agonists: 5-year follow-up data." The Lancet Diabetes & Endocrinology. 2021.
• Lindberg H, et al. "Tirzepatide vs semaglutide: comparative efficacy in real-world settings." Obesity Reviews. 2023.
• Lindberg H, et al. "Predictors of weight loss response to liraglutide 3.0mg." International Journal of Obesity. 2019.
• Lindberg H, Kahn CR. "Brown adipose tissue activation and GLP-1: mechanistic insights." Cell Metabolism. 2015.

As a member of the Scientific Advisory Board, Dr. Lindberg brings his expertise in endocrinology and GLP-1 agonists to review educational content. He ensures scientific accuracy for articles concerning semaglutide, tirzepatide, and weight loss therapies.